Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Lancet Infect Dis
    September 2021
  1. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Addendum needed on COVID-19 travel study - Authors' reply.
    Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00562.
    >> Share

  2. HO CS, Feng PI, Narita M, Stout JE, et al
    Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.
    Lancet Infect Dis. 2021 Sep 6. pii: S1473-3099(21)00145.
    >> Share

  3. KIRBY T
    Marta Lado-Ebola, HIV, sexual health and more.
    Lancet Infect Dis. 2021;21:1224.
    >> Share

    August 2021
  4. DAMHORST GL, Watts A, Hernandez-Romieu A, Mel N, et al
    Acanthamoeba castellanii encephalitis in a patient with AIDS: a case report and literature review.
    Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(20)30933.
    >> Share

  5. BURKI T
    Infected blood inquiry in the UK.
    Lancet Infect Dis. 2021;21:1078-1079.
    >> Share

    July 2021
  6. NAKKAZI E
    Uganda's Sexual Offences Bill-a step backwards.
    Lancet Infect Dis. 2021;21:920.
    >> Share

    June 2021
  7. KENYON G
    Hong Shang-leading HIV/AIDS research in China.
    Lancet Infect Dis. 2021;21:779.
    >> Share

  8. BURKI T
    HIV in the age of COVID-19.
    Lancet Infect Dis. 2021;21:774-775.
    >> Share

  9. VASAN S, Pitisuttithum P
    Vaccine development lessons between HIV and COVID-19.
    Lancet Infect Dis. 2021;21:759-761.
    >> Share

  10. KIRBY T
    Mario Poljak - Central Europe's pioneer in diagnostics.
    Lancet Infect Dis. 2021;21:780.
    >> Share

  11. SAMARASEKERA U
    Linda-Gail Bekker-a leader at the service of the world.
    Lancet Infect Dis. 2021;21:778.
    >> Share

  12. KAZI F, Mushtaq A
    Loretta Sweet Jemmott-a voice for the voiceless.
    Lancet Infect Dis. 2021;21:777.
    >> Share

    May 2021
  13. ARORA U, Garg P, Agarwal S, Nischal N, et al
    Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis.
    Lancet Infect Dis. 2021 May 20. pii: S1473-3099(20)30765.
    >> Share

  14. DAL-RE R, Bekker LG, Gluud C, Holm S, et al
    Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
    Lancet Infect Dis. 2021 May 18. pii: S1473-3099(21)00263.
    >> Share

  15. CHALMERS RM, Alexander C
    Defining the diagnosis of cryptosporidiosis.
    Lancet Infect Dis. 2021;21:589-590.
    >> Share

  16. KAZI F, Mushtaq A
    CROI 2021.
    Lancet Infect Dis. 2021;21:606.
    >> Share

    April 2021
  17. CHAPPELL KJ, Mordant FL, Li Z, Wijesundara DK, et al
    Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00200.
    >> Share

  18. STOTT KE, Loyse A, Jarvis JN, Alufandika M, et al
    Cryptococcal meningoencephalitis: time for action.
    Lancet Infect Dis. 2021 Apr 16. pii: S1473-3099(20)30771.
    >> Share

  19. SPINELLI MA, Rutherford G, Gandhi M
    Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply.
    Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00210.
    >> Share

    March 2021
  20. EL HALABI J, Palmer N, McDuffie M, Golub JJ, et al
    Measuring health-care delays among privately insured patients with tuberculosis in the USA: an observational cohort study.
    Lancet Infect Dis. 2021 Mar 23. pii: S1473-3099(20)30732.
    >> Share

  21. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study.
    Lancet Infect Dis. 2021 Mar 22. pii: S1473-3099(21)00134.
    >> Share

  22. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A, Hidalgo A, et al
    Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(20)30983.
    >> Share

  23. VAN DIJCK C, Tsoumanis A, Rotsaert A, Vuylsteke B, et al
    Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
    Lancet Infect Dis. 2021 Mar 4. pii: S1473-3099(20)30778.
    >> Share

  24. POZNIAK A, Meintjes G
    Raltegravir in patients with tuberculosis.
    Lancet Infect Dis. 2021 Mar 2. pii: S1473-3099(20)30937.
    >> Share

  25. DE CASTRO N, Marcy O, Chazallon C, Messou E, et al
    Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    Lancet Infect Dis. 2021 Mar 2. pii: S1473-3099(20)30869.
    >> Share

    February 2021
  26. DODD PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, et al
    Quantifying the global number of tuberculosis survivors: a modelling study.
    Lancet Infect Dis. 2021 Feb 25. pii: S1473-3099(20)30919.
    >> Share

  27. SPINELLI MA, Glidden DV, Gennatas ED, Bielecki M, et al
    Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.
    Lancet Infect Dis. 2021 Feb 22. pii: S1473-3099(20)30982.
    >> Share

  28. PRENTICE S, Nassanga B, Webb EL, Akello F, et al
    BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
    Lancet Infect Dis. 2021 Feb 17. pii: S1473-3099(20)30653.
    >> Share

  29. INZAULE SC, Tessema SK, Kebede Y, Ogwell Ouma AE, et al
    Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30939.
    >> Share

  30. DOOLEY KE, Rosenkranz SL, Conradie F, Moran L, et al
    QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30770.
    >> Share

  31. MAKONI M
    New tuberculosis tests and drugs remain out of reach.
    Lancet Infect Dis. 2021;21:174.
    >> Share

    January 2021
  32. SCRIBA TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, et al
    Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
    Lancet Infect Dis. 2021 Jan 25. pii: S1473-3099(20)30914.
    >> Share

    December 2020
  33. HENGEL B, Causer L, Matthews S, Smith K, et al
    A decentralised point-of-care testing model to address inequities in the COVID-19 response.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30859.
    >> Share

  34. SAMER C, Lacombe K, Calmy A
    Cyber harassment of female scientists will not be the new norm.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30944.
    >> Share

  35. POUSTCHI H, Darvishian M, Mohammadi Z, Shayanrad A, et al
    SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30858.
    >> Share

  36. NKEREUWEM E, Togun T, Gomez MP, Szekely R, et al
    Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study.
    Lancet Infect Dis. 2020 Dec 11. pii: S1473-3099(20)30598.
    >> Share

  37. HAMADA Y, Gupta RK, Matteelli A, Abubakar I, et al
    Predictive performance of interferon-gamma release assays and tuberculin skin tests.
    Lancet Infect Dis. 2020;20:1371-1372.
    >> Share

    November 2020
  38. KAZI F, Mushtaq A
    Primary care of patients with HIV.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30925.
    >> Share

  39. SHROUFI A, Chiller T, Jordan A, Denning DW, et al
    Ending deaths from HIV-related cryptococcal meningitis by 2030.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30909.
    >> Share

  40. KENYON C, Manoharan-Basil SS
    Macrolide consumption and resistance in Mycoplasma genitalium.
    Lancet Infect Dis. 2020;20:1235-1236.
    >> Share

    October 2020
  41. ETARD JF
    Immunity to Ebola virus: the full picture is being revealed.
    Lancet Infect Dis. 2020 Oct 13. pii: S1473-3099(20)30793.
    >> Share

  42. KIRBY T
    Evelina Tacconelli-two viruses, two wars.
    Lancet Infect Dis. 2020;20:1132.
    >> Share

    September 2020
  43. HIRONS A, Khoury G, Purcell DFJ
    Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.
    Lancet Infect Dis. 2020 Sep 25. pii: S1473-3099(20)30328.
    >> Share

    August 2020
  44. MADHI SA, Mutsaerts EA, Izu A, Boyce W, et al
    Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.
    Lancet Infect Dis. 2020 Aug 25. pii: S1473-3099(20)30289.
    >> Share

    July 2020
  45. KIRBY T
    Cabotegravir, a new option for PrEP.
    Lancet Infect Dis. 2020;20:781.
    >> Share

    June 2020
  46. RODRIGUEZ TUDELA JL, Cole DC, Ravasi G, Bruisma N, et al
    Integration of fungal diseases into health systems in Latin America.
    Lancet Infect Dis. 2020 Jun 30. pii: S1473-3099(20)30469.
    >> Share

  47. SENA AC, Bachmann L, Johnston C, Wi T, et al
    Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.
    Lancet Infect Dis. 2020 Jun 19. pii: S1473-3099(20)30171.
    >> Share

    May 2020
  48. DIVALA TH, Fielding KL, Kandulu C, Nliwasa M, et al
    Utility of broad-spectrum antibiotics for diagnosing pulmonary tuberculosis in adults: a systematic review and meta-analysis.
    Lancet Infect Dis. 2020 May 18. pii: S1473-3099(20)30143.
    >> Share

    April 2020
  49. YANG F, Zhang TP, Tang W, Ong JJ, et al
    Pay-it-forward gonorrhoea and chlamydia testing among men who have sex with men in China: a randomised controlled trial.
    Lancet Infect Dis. 2020 Apr 28. pii: S1473-3099(20)30172.
    >> Share

  50. FOLEGATTI PM, Bittaye M, Flaxman A, Lopez FR, et al
    Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
    Lancet Infect Dis. 2020 Apr 20. pii: S1473-3099(20)30160.
    >> Share

  51. GROOME MJ, Fairlie L, Morrison J, Fix A, et al
    Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30001.
    >> Share

  52. MUSHTAQ A
    New guidelines for latent tuberculosis.
    Lancet Infect Dis. 2020;20:414.
    >> Share

  53. CHOUCHANA L, Pariente A, Pannier E, Tsatsaris V, et al
    Dolutegravir and neural tube defects: a new insight.
    Lancet Infect Dis. 2020;20:405-406.
    >> Share

    March 2020
  54. KALLAS EG, Precioso AR, Palacios R, Thome B, et al
    Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial.
    Lancet Infect Dis. 2020 Mar 24. pii: S1473-3099(20)30023.
    >> Share

  55. MARAIS BJ, Chakaya J, Swaminathan S, Fox GJ, et al
    Tackling long-term morbidity and mortality after successful tuberculosis treatment.
    Lancet Infect Dis. 2020 Mar 23. pii: S1473-3099(20)30167.
    >> Share

  56. TAPIA MD, Sow SO, Ndiaye BP, Mbaye KD, et al
    Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in adults in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2020 Mar 19. pii: S1473-3099(20)30016.
    >> Share

  57. BARR DA, Lewis JM, Feasey N, Schutz C, et al
    Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data.
    Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(19)30695.
    >> Share

  58. KELLER PM, Furrer H
    Think tuberculosis-but is thinking enough?
    Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(20)30138.
    >> Share

  59. MBOPI-KEOU FX, Kalla GCM, Anankeu P, Pondi JE, et al
    Launching HIV self-testing in a multicultural setting in Cameroon.
    Lancet Infect Dis. 2020;20:286-287.
    >> Share

    February 2020
  60. WILLIAMS CM, Abdulwhhab M, Birring SS, De Kock E, et al
    Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies.
    Lancet Infect Dis. 2020 Feb 18. pii: S1473-3099(19)30707.
    >> Share

  61. LAXMINARAYAN R, Van Boeckel T, Frost I, Kariuki S, et al
    The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later.
    Lancet Infect Dis. 2020 Feb 11. pii: S1473-3099(20)30003.
    >> Share

    January 2020
  62. TOWN K, Field N, Harris SR, Sanchez-Buso L, et al
    Phylogenomic analysis of Neisseria gonorrhoeae transmission to assess sexual mixing and HIV transmission risk in England: a cross-sectional, observational, whole-genome sequencing study.
    Lancet Infect Dis. 2020 Jan 21. pii: S1473-3099(19)30610.
    >> Share

  63. JOLLY AM, Dillon JR
    Phylogenomic analysis of Neisseria gonorrhoeae: a promising tool for tracking putative gonococcal sexual networks.
    Lancet Infect Dis. 2020 Jan 21. pii: S1473-3099(19)30751.
    >> Share

  64. CLARKE DK, Xu R, Matassov D, Latham TE, et al
    Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
    Lancet Infect Dis. 2020 Jan 14. pii: S1473-3099(19)30614.
    >> Share

  65. DONOVAN J, Thu DDA, Phu NH, Dung VTM, et al
    Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study.
    Lancet Infect Dis. 2020 Jan 7. pii: S1473-3099(19)30649.
    >> Share

  66. CRESSWELL FV, Tugume L, Bahr NC, Kwizera R, et al
    Xpert MTB/RIF Ultra for the diagnosis of HIV-associated tuberculous meningitis: a prospective validation study.
    Lancet Infect Dis. 2020 Jan 7. pii: S1473-3099(19)30550.
    >> Share

  67. BROGER T, Muyoyeta M, Kerkhoff AD, Denkinger CM, et al
    Tuberculosis test results using fresh versus biobanked urine samples with FujiLAM.
    Lancet Infect Dis. 2020;20:22-23.
    >> Share

    December 2019
  68. COTTON MF, Rabie H
    HIV outbreak in children in Pakistan: localised or more widespread?
    Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30746.
    >> Share

  69. MIR F, Mahmood F, Siddiqui AR, Baqi S, et al
    HIV infection predominantly affecting children in Sindh, Pakistan, 2019: a cross-sectional study of an outbreak.
    Lancet Infect Dis. 2019 Dec 19. pii: S1473-3099(19)30743.
    >> Share

  70. AUGUSTO GF
    HIV self-testing kits enjoy successful launch in Portugal.
    Lancet Infect Dis. 2019;19:1289.
    >> Share

  71. SHARLAND M, Gandra S, Huttner B, Moja L, et al
    Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool.
    Lancet Infect Dis. 2019;19:1278-1280.
    >> Share

    November 2019
  72. LOOKER KJ, Welton NJ, Sabin KM, Dalal S, et al
    Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data.
    Lancet Infect Dis. 2019 Nov 18. pii: S1473-3099(19)30470.
    >> Share

  73. DARA M, Ehsani S, Mozalevskis A, Vovc E, et al
    Tuberculosis, HIV, and viral hepatitis diagnostics in eastern Europe and central Asia: high time for integrated and people-centred services.
    Lancet Infect Dis. 2019 Nov 15. pii: S1473-3099(19)30524.
    >> Share

    October 2019

  74. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017.
    Lancet Infect Dis. 2019 Oct 30. pii: S1473-3099(19)30410.
    >> Share

  75. HILL SC, Vasconcelos J, Neto Z, Jandondo D, et al
    Emergence of the Asian lineage of Zika virus in Angola: an outbreak investigation.
    Lancet Infect Dis. 2019;19:1138-1147.
    >> Share

  76. BLOWER S, Okano JT
    Precision public health and HIV in Africa.
    Lancet Infect Dis. 2019;19:1050-1052.
    >> Share

    September 2019

  77. The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet Infect Dis. 2019 Sep 24. pii: S1473-3099(19)30418.
    >> Share

  78. AKIYAMA MJ, Cleland CM, Lizcano JA, Cherutich P, et al
    Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Lancet Infect Dis. 2019 Sep 17. pii: S1473-3099(19)30264.
    >> Share

  79. RAHIMI S
    Dolutegravir becomes first choice for HIV.
    Lancet Infect Dis. 2019;19:937-938.
    >> Share

    August 2019
  80. AGINS BD, Ikeda DJ, Reid MJA, Goosby E, et al
    Improving the cascade of global tuberculosis care: moving from the "what" to the "how" of quality improvement.
    Lancet Infect Dis. 2019 Aug 22. pii: S1473-3099(19)30420.
    >> Share

  81. RHEIN J, Huppler Hullsiek K, Tugume L, Nuwagira E, et al
    Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.
    Lancet Infect Dis. 2019;19:843-851.
    >> Share

  82. TENFORDE MW, Jarvis JN
    HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities.
    Lancet Infect Dis. 2019;19:793-794.
    >> Share

    July 2019
  83. MUHINDO MK, Jagannathan P, Kakuru A, Opira B, et al
    Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
    Lancet Infect Dis. 2019 Jul 12. pii: S1473-3099(19)30299.
    >> Share

  84. TENFORDE MW, Mokomane M, Leeme TB, Tlhako N, et al
    Mortality in adult patients with culture-positive and culture-negative meningitis in the Botswana national meningitis survey: a prevalent cohort study.
    Lancet Infect Dis. 2019;19:740-749.
    >> Share

  85. ARIF F
    HIV crisis in Sindh, Pakistan: the tip of the iceberg.
    Lancet Infect Dis. 2019;19:695-696.
    >> Share

  86. THE LANCET INFECTIOUS DISEASES
    HIV epidemics in Pakistan.
    Lancet Infect Dis. 2019;19:671.
    >> Share

    June 2019
  87. LIN C, Slama J, Gonzalez P, Goodman MT, et al
    Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis.
    Lancet Infect Dis. 2019 Jun 13. pii: S1473-3099(19)30164.
    >> Share

  88. SUAREZ I, Maria Funger S, Jung N, Lehmann C, et al
    Severe disseminated tuberculosis in HIV-negative refugees.
    Lancet Infect Dis. 2019 Jun 7. pii: S1473-3099(19)30162.
    >> Share

    May 2019
  89. BROGER T, Sossen B, du Toit E, Kerkhoff AD, et al
    Novel lipoarabinomannan point-of-care tuberculosis test for people with HIV: a diagnostic accuracy study.
    Lancet Infect Dis. 2019 May 30. pii: S1473-3099(19)30001.
    >> Share

  90. DRAIN PK, Heichman KA, Wilson D
    A new point-of-care test to diagnose tuberculosis.
    Lancet Infect Dis. 2019 May 30. pii: S1473-3099(19)30053.
    >> Share

  91. BURKI T
    Tuberculosis mortality targets off-track.
    Lancet Infect Dis. 2019;19:472.
    >> Share

    April 2019
  92. BURKI T
    The end of HIV in the USA.
    Lancet Infect Dis. 2019;19:365-366.
    >> Share

    March 2019
  93. VAN EIJK AM, Larsen DA, Kayentao K, Koshy G, et al
    Effect of Plasmodium falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis.
    Lancet Infect Dis. 2019 Mar 25. pii: S1473-3099(18)30732.
    >> Share

  94. INZAULE SC, Hamers RL, Doherty M, Shafer RW, et al
    Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens.
    Lancet Infect Dis. 2019 Mar 19. pii: S1473-3099(18)30710.
    >> Share

  95. WAHID B
    An update on the severe outbreak of HIV in Kot Imrana, Pakistan.
    Lancet Infect Dis. 2019;19:241.
    >> Share

  96. GOFF DA, Kullar R, Laxminarayan R, Mendelson M, et al
    Twitter to engage, educate, and advocate for global antibiotic stewardship and antimicrobial resistance.
    Lancet Infect Dis. 2019;19:229-231.
    >> Share

  97. BENGTSON AM, Sanfilippo AM, Hughes BL, Savitz DA, et al
    Maternal immunisation and neonatal infection of hepatitis A or B virus - Authors' reply.
    Lancet Infect Dis. 2019;19:238-239.
    >> Share

  98. ZHOU YH
    Maternal immunisation and neonatal infection of hepatitis A or B virus.
    Lancet Infect Dis. 2019;19:238.
    >> Share

    February 2019
  99. ZURCHER K, Ballif M, Fenner L, Borrell S, et al
    Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study.
    Lancet Infect Dis. 2019 Feb 7. pii: S1473-3099(18)30673.
    >> Share

  100. ABOUD M, Kaplan R, Lombaard J, Zhang F, et al
    Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
    Lancet Infect Dis. 2019 Feb 4. pii: S1473-3099(19)30036.
    >> Share

  101. WALKER S, Stoove M, Wilson M, Higgs P, et al
    Understanding HIV and hepatitis C virus risk among incarcerated young men with histories of injecting drug use.
    Lancet Infect Dis. 2019;19:130-131.
    >> Share

    January 2019
  102. WHITWORTH HS, Badhan A, Boakye AA, Takwoingi Y, et al
    Clinical utility of existing and second-generation interferon-gamma release assays for diagnostic evaluation of tuberculosis: an observational cohort study.
    Lancet Infect Dis. 2019 Jan 14. pii: S1473-3099(18)30613.
    >> Share

  103. LI KT, Tang W, Wu D, Huang W, et al
    Pay-it-forward strategy to enhance uptake of dual gonorrhea and chlamydia testing among men who have sex with men in China: a pragmatic, quasi-experimental study.
    Lancet Infect Dis. 2019;19:76-82.
    >> Share

  104. THE LANCET INFECTIOUS DISEASES
    HIV in Europe: a long road still lies ahead.
    Lancet Infect Dis. 2019;19:1.
    >> Share

    December 2018
  105. CUDAHY PGT, Andrews JR, Bilinski A, Dowdy DW, et al
    Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings.
    Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30443.
    >> Share

  106. KHAN PY, Yates TA, Osman M, Warren RM, et al
    Transmission of drug-resistant tuberculosis in HIV-endemic settings.
    Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30537.
    >> Share

  107. PETERS JS, Andrews JR, Hatherill M, Hermans S, et al
    Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings.
    Lancet Infect Dis. 2018 Dec 13. pii: S1473-3099(18)30477.
    >> Share

  108. LINDSEY BB, Armitage EP, Kampmann B, de Silva TI, et al
    The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review.
    Lancet Infect Dis. 2018 Dec 12. pii: S1473-3099(18)30490.
    >> Share

  109. BENGTSON AM, Sanfilippo AM, Hughes BL, Savitz DA, et al
    Maternal immunisation to improve the health of HIV-exposed infants.
    Lancet Infect Dis. 2018 Dec 7. pii: S1473-3099(18)30545.
    >> Share

  110. BRINK AJ, Mendelson M
    Be AWaRe: new metrics for paediatric antibiotic stewardship.
    Lancet Infect Dis. 2018 Dec 3. pii: S1473-3099(18)30557.
    >> Share


  111. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study.
    Lancet Infect Dis. 2018;18:1329-1349.
    >> Share

  112. BURKI T
    HIV in China: a changing epidemic.
    Lancet Infect Dis. 2018;18:1311-1312.
    >> Share

    November 2018
  113. HEMELAAR J, Elangovan R, Yun J, Dickson-Tetteh L, et al
    Global and regional molecular epidemiology of HIV-1, 1990-2015: a systematic review, global survey, and trend analysis.
    Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30647.
    >> Share

  114. PARASKEVIS D, Hatzakis A
    Global molecular epidemiology of HIV-1: the chameleon challenge.
    Lancet Infect Dis. 2018 Nov 30. pii: S1473-3099(18)30687.
    >> Share

  115. DELANY-MORETLWE S, Lombard C, Baron D, Bekker LG, et al
    Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2018;18:1241-1250.
    >> Share

  116. GENG EH, Glidden DV, Padian N
    Strengthening HIV-prevention trials: a dose of implementation science?
    Lancet Infect Dis. 2018;18:1166-1168.
    >> Share

    October 2018
  117. STONE J, Fraser H, Lim AG, Walker JG, et al
    Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis.
    Lancet Infect Dis. 2018 Oct 29. pii: S1473-3099(18)30469.
    >> Share

  118. LOYSE A, Burry J, Cohn J, Ford N, et al
    Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
    Lancet Infect Dis. 2018 Oct 18. pii: S1473-3099(18)30493.
    >> Share

  119. VARIAVA E, Martinson N
    Occult rifampicin-resistant tuberculosis: better assays are needed.
    Lancet Infect Dis. 2018 Oct 17. pii: S1473-3099(18)30550.
    >> Share

  120. KISSINGER P, Muzny CA, Mena LA, Lillis RA, et al
    Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women: an open-label, randomised controlled trial.
    Lancet Infect Dis. 2018 Oct 5. pii: S1473-3099(18)30423.
    >> Share

  121. HUGHES G, Fifer H
    Point-of-care tests for chlamydia and gonorrhoea in Indigenous communities.
    Lancet Infect Dis. 2018;18:1054-1055.
    >> Share

    September 2018
  122. DIVALA TH, Mungwira RG, Mawindo PM, Nyirenda OM, et al
    Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
    Lancet Infect Dis. 2018 Sep 5. pii: S1473-3099(18)30415.
    >> Share

    August 2018
  123. ADENIS AA, Valdes A, Cropet C, McCotter OZ, et al
    Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: a modelling study.
    Lancet Infect Dis. 2018 Aug 23. pii: S1473-3099(18)30354.
    >> Share

  124. BURKI T
    The USA's HIV problem.
    Lancet Infect Dis. 2018;18:840-841.
    >> Share

    July 2018
  125. SAGARA I, Healy SA, Assadou MH, Gabriel EE, et al
    Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults.
    Lancet Infect Dis. 2018 Jul 27. pii: S1473-3099(18)30344.
    >> Share

  126. WOODHALL SC, Gorwitz RJ, Migchelsen SJ, Gottlieb SL, et al
    Advancing the public health applications of Chlamydia trachomatis serology.
    Lancet Infect Dis. 2018 Jul 5. pii: S1473-3099(18)30159.
    >> Share

  127. NKENGASONG JN, Mbopi-Keou FX, Peeling RW, Yao K, et al
    Laboratory medicine in Africa since 2008: then, now, and the future.
    Lancet Infect Dis. 2018 Jul 3. pii: S1473-3099(18)30120.
    >> Share

  128. KALLA GCM, Voundi EV, Angwafo F 3rd, Belec L, et al
    Mass screening for hepatitis B and C and HIV in sub-Saharan Africa.
    Lancet Infect Dis. 2018;18:716.
    >> Share

    June 2018
  129. ZAID M, Afzal MS
    HIV outbreak in Pakistan.
    Lancet Infect Dis. 2018;18:601.
    >> Share

    May 2018
  130. MENDELSON M, Hamer DH
    Out of the frying pan and into the fire.
    Lancet Infect Dis. 2018 May 17. pii: S1473-3099(18)30244.
    >> Share

  131. SEEDAT F, Hargreaves S, Nellums LB, Ouyang J, et al
    How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review.
    Lancet Infect Dis. 2018 May 16. pii: S1473-3099(18)30117.
    >> Share

    April 2018
  132. VARIAVA E, Martinson N
    Drug-resistant tuberculosis: the rise of the monos.
    Lancet Infect Dis. 2018 Apr 20. pii: S1473-3099(18)30247.
    >> Share

  133. MENDELSON M, Brink A, Gouws J, Mbelle N, et al
    The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa.
    Lancet Infect Dis. 2018 Apr 16. pii: S1473-3099(18)30119.
    >> Share

  134. LABORDE-BALEN G, Taverne B, Ndour CT, Kouanfack C, et al
    The fourth HIV epidemic.
    Lancet Infect Dis. 2018;18:379-380.
    >> Share

    March 2018
  135. WALZL G, McNerney R, du Plessis N, Bates M, et al
    Tuberculosis: advances and challenges in development of new diagnostics and biomarkers.
    Lancet Infect Dis. 2018 Mar 23. pii: S1473-3099(18)30111.
    >> Share

  136. FIFER H, Cole M, Hughes G, Padfield S, et al
    Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study.
    Lancet Infect Dis. 2018 Mar 6. pii: S1473-3099(18)30122.
    >> Share

  137. BOYLES T
    Xpert Ultra's place in the diagnosis of tuberculous meningitis.
    Lancet Infect Dis. 2018;18:248-249.
    >> Share

    February 2018
  138. FERLAZZO G, Mohr E, Laxmeshwar C, Hewison C, et al
    Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Lancet Infect Dis. 2018 Feb 13. pii: S1473-3099(18)30100.
    >> Share

  139. KOUDOU BG, de Souza DK, Biritwum NK, Bougma R, et al
    Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary?
    Lancet Infect Dis. 2018 Feb 2. pii: S1473-3099(18)30069.
    >> Share

  140. COLEMAN BW, Sereti I, Bishop R, Smith BR, et al
    Upbeat nystagmus in an HIV-positive patient with a tuberculoma in the medulla.
    Lancet Infect Dis. 2018;18:225.
    >> Share

  141. ASSEFA Y
    Expansion of the WHO public health approach to HIV.
    Lancet Infect Dis. 2018;18:143-144.
    >> Share

    January 2018
  142. DESAI M, Hill J, Fernandes S, Walker P, et al
    Prevention of malaria in pregnancy.
    Lancet Infect Dis. 2018 Jan 30. pii: S1473-3099(18)30064.
    >> Share

  143. MCCLELLAND RS, Lingappa JR, Srinivasan S, Kinuthia J, et al
    Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study.
    Lancet Infect Dis. 2018 Jan 25. pii: S1473-3099(18)30058.
    >> Share

  144. PASSMORE JS, Jaspan HB
    Vaginal microbes, inflammation, and HIV risk in African women.
    Lancet Infect Dis. 2018 Jan 25. pii: S1473-3099(18)30061.
    >> Share

  145. VAN LAARHOVEN A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, et al
    Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study.
    Lancet Infect Dis. 2018 Jan 23. pii: S1473-3099(18)30053.
    >> Share

  146. DARA M, Zachariah R
    Ending tuberculosis calls for leaving no one behind.
    Lancet Infect Dis. 2018 Jan 8. pii: S1473-3099(17)30746.
    >> Share

  147. ZOU H, Tucker JD, Fan S, Xu J, et al
    Learning about HIV the hard way: HIV among Chinese MSM attending university.
    Lancet Infect Dis. 2018;18:16-18.
    >> Share

    December 2017
  148. MOLINA JM, Charreau I, Chidiac C, Pialoux G, et al
    Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.
    Lancet Infect Dis. 2017 Dec 8. pii: S1473-3099(17)30725.
    >> Share


  149. The global burden of tuberculosis: results from the Global Burden of Disease Study 2015.
    Lancet Infect Dis. 2017 Dec 6. pii: S1473-3099(17)30703.
    >> Share

    November 2017
  150. YERLY S, Calmy A
    Time to overcome pretreatment HIV drug resistance.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30709.
    >> Share

  151. DORMAN SE, Schumacher SG, Alland D, Nabeta P, et al
    Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30691.
    >> Share

  152. GUPTA RK, Gregson J, Parkin N, Haile-Selassie H, et al
    HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Lancet Infect Dis. 2017 Nov 30. pii: S1473-3099(17)30702.
    >> Share

  153. LIN C, Franceschi S, Clifford GM
    Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30653.
    >> Share

  154. HERMANS LE, Moorhouse M, Carmona S, Grobbee DE, et al
    Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30681.
    >> Share

  155. CASTAGNA A, Galli L
    Stepping up HIV-1 low-level viraemia surveillance in South Africa.
    Lancet Infect Dis. 2017 Nov 17. pii: S1473-3099(17)30680.
    >> Share

  156. ZELENEV A, Li J, Mazhnaya A, Basu S, et al
    Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.
    Lancet Infect Dis. 2017 Nov 15. pii: S1473-3099(17)30676.
    >> Share

  157. HILL AM, Venter F
    The unexpected success of NRTIs in second-line treatment.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30631.
    >> Share

  158. HAKIM JG, Thompson J, Kityo C, Hoppe A, et al
    Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
    Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630.
    >> Share

  159. COUSINS S
    HIV and antenatal care in Sri Lanka: a global health success.
    Lancet Infect Dis. 2017;17:1126.
    >> Share

    October 2017
  160. ABEL L, Fellay J, Haas DW, Schurr E, et al
    Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.
    Lancet Infect Dis. 2017 Oct 27. pii: S1473-3099(17)30623.
    >> Share

  161. FORD N, Ball A, Baggaley R, Vitoria M, et al
    The WHO public health approach to HIV treatment and care: looking back and looking ahead.
    Lancet Infect Dis. 2017 Oct 20. pii: S1473-3099(17)30482.
    >> Share

  162. CAMBIANO V, Miners A, Dunn D, McCormack S, et al
    Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Lancet Infect Dis. 2017 Oct 17. pii: S1473-3099(17)30540.
    >> Share

  163. REVILL P, Dwyer E
    Pre-exposure prophylaxis is cost-effective for HIV in the UK.
    Lancet Infect Dis. 2017 Oct 17. pii: S1473-3099(17)30594.
    >> Share

    September 2017
  164. BEIGEL JH, Bao Y, Beeler J, Manosuthi W, et al
    Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
    Lancet Infect Dis. 2017 Sep 22. pii: S1473-3099(17)30476.
    >> Share

  165. BAHR NC, Nuwagira E, Evans EE, Cresswell FV, et al
    Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study.
    Lancet Infect Dis. 2017 Sep 14. pii: S1473-3099(17)30474.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016